Voyager Therapeutics (VYGR) PT Lowered to $8 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
May 13, 2024 4:01 PM EDT- Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimers disease; expect to begin single ascending dose trial in the coming weeks -
- Development candidates selected for Neurocrine-partnered GBA1 and Friedreichs Ataxia gene therapy programs; potential for three gene therapies, including SOD1-ALS, to enter the clinic in 2025 -
- Appointed neurology clinical development expert Toby Ferguson, M.D., Ph.D., as Chief Medical Officer -
- Strong cash position of approximately $400 million as of March 31, 2024;... More
